E 10215Alternative Names: E-10215
Latest Information Update: 05 Apr 2016
At a glance
- Originator Elorac
- Class Antiacnes; Antibacterials
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acne
Most Recent Events
- 05 Apr 2016 Phase-I development is ongoing in USA
- 14 Jan 2015 Phase-I clinical trials in Acne in USA (PO)